Table 1 Retrospective trials enrolling patients with HCC who received TIPS placement
From: Risks and benefits of TIPS in HCC and other liver malignancies: a literature review
Author | Main exclusion criteria | Enrolled patients with HCC + TIPS (n) | Pre-TIPS C-P stage (A/B/C) | BCLC (A/B/C/D) | Clinical response of CSPH to TIPS (partial/complete remission) (%) | Median survival (months) |
|---|---|---|---|---|---|---|
Yan H, et al. 2022 [18] | Tumour volume > 70% of the liver, primary CCC, multiple liver cysts, liver failure, severe cardio-pulmonary dysfunction, biliary and pancreatic obstruction | 123 | 32/79/12 | 14/27/71/11 | 18.7/74.8 | 10.7 |
Qiu Z, et al. 2022 [15]. | Tumour volume > 70% of the liver, lung/bone metastases, multiple liver cysts, congestive heart failure, sepsis, moderate/severe pulmonary hypertension, biliary obstruction, severe coagulopathy | 42 | 12/26/4 | 0/0/38/4 | 20/72 | 9.6 |
Luo S., et al. 2019 [16] | Portal vein thrombosis, history of HE, severe right-sided heart failure, polycystic liver disease, dilated biliary ducts, age > 75 years, bilirubin > 5 mg/dL, creatinine > 3 mg/dL, C–P score > 11, MELD score > 18, sepsis, spontaneous bacterial peritonitis, patients who had undergone transplantation | 217 | 54/129/34 | 18/107/53/34 | NA | 50 |
Liu L., et al., 2014 [13] | Treatments for CSPH other than TIPS, no PVTT | 58 | 11/34/13 | 0/0/35/23 | 15/80 | 2.5 |
Bettinger D, et al. 2015 [14] | Intra– or extrahepatic cholangiocarcinoma or metastases from extrahepatic malignancies | 40 | 3/29/8 | NA | 74 and 1001 | 6.1 |